WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
|
Votes For |
Votes Withheld |
||
Director |
# |
% |
# |
% |
Dr. |
46,902,346 |
88.3 % |
6,234,676 |
11.7 % |
Dr. |
46,965,380 |
88.4 % |
6,171,642 |
11.6 % |
Donald Archibald |
44,900,287 |
84.5 % |
8,236,735 |
15.5 % |
|
46,963,057 |
88.4 % |
6,173,965 |
11.6 % |
|
46,900,723 |
88.3 % |
6,236,299 |
11.7 % |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
|
Votes For |
|
Director |
# |
% |
Appointment of |
51,882,364 |
87.6 % |
The proposed sale of the shares of |
46,996,397 |
88.4 % |
To authorize the Corporation's board of directors, at its sole discretion, to |
48,853,362 |
82.5 % |
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated
About
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: info@willowbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html
SOURCE